GlassScriptPhysician profile
Jovan C Baker
NPI 1528694544
$880.84
in general payments reported to CMS, 2019-2025
12 companies · $41.24 in 2025
The $41.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $394 · 2024: $446 · 2025: $41.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.75 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Lilly USA, LLC | $96.35 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $71.41 | 2023-2024 | Stelara, Simponi, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $54.75 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $42.11 | 2023-2024 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $34.72 | 2023-2024 | Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $29.88 | 2023-2024 | Linzess |
| Medtronic, INC. | $26.25 | 2024 | Solitaire X |
| Regeneron Healthcare Solutions, INC. | $25.29 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $22.61 | 2024 | |
| Merck Sharp & Dohme LLC | $21.78 | 2023 | Dificid |
| Exact Sciences Corporation | $15.94 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jovan Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.